BRAF V600E mutation and papillary thyroid cancer

JAMA

Volumn 310, Issue 5, 2013, Pages 534-

  Ciarrocchi, Alessia ^a   Cavuto, Silvio ^a   Piana, Simonetta ^a  

^a S MARIA NUOVA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; GLUTAMIC ACID; TUMOR MARKER; VALINE;

BRAF GENE; CANCER MORTALITY; CANCER PROGNOSIS; CLINICAL FEATURE; DISEASE ASSOCIATION; DISTANT METASTASIS; GENE MUTATION; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC VARIABILITY; HUMAN; LETTER; METASTASIS POTENTIAL; PAPILLARY THYROID CANCER; PRIORITY JOURNAL; THYROID CANCER; CARCINOMA; FEMALE; GENETICS; MALE; MORTALITY; NOTE; NUCLEOTIDE SEQUENCE; THYROID TUMOR;

CARCINOMA; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; MALE; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS;

EID: 84881257644     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.8589     Document Type: Letter

References (2)

1. Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 2013;309(14):1493-1501.
2. Sancisi V, Nicoli D, Ragazzi M, Piana S, Ciarrocchi A. BRAF V600E mutation does not mean distant metastasis in thyroid papillary carcinomas. J Clin Endocrinol Metab. 2012;97(9):1745-1749.